作者更正：高危可切除黑色素瘤的新辅助免疫检查点阻断。

Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.

作者信息

Amaria Rodabe N, Reddy Sangeetha M, Tawbi Hussein A, Davies Michael A, Ross Merrick I, Glitza Isabella C, Cormier Janice N, Lewis Carol, Hwu Wen-Jen, Hanna Ehab, Diab Adi, Wong Michael K, Royal Richard, Gross Neil, Weber Randal, Lai Stephen Y, Ehlers Richard, Blando Jorge, Milton Denái R, Woodman Scott, Kageyama Robin, Wells Daniel K, Hwu Patrick, Patel Sapna P, Lucci Anthony, Hessel Amy, Lee Jeffrey E, Gershenwald Jeffrey, Simpson Lauren, Burton Elizabeth M, Posada Liberty, Haydu Lauren, Wang Linghua, Zhang Shaojun, Lazar Alexander J, Hudgens Courtney W, Gopalakrishnan Vancheswaran, Reuben Alexandre, Andrews Miles C, Spencer Christine N, Prieto Victor, Sharma Padmanee, Allison James, Tetzlaff Michael T, Wargo Jennifer A

机构信息

Department of Melanoma Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.

Department of Breast Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.

出版信息

Nat Med. 2018 Dec;24(12):1941. doi: 10.1038/s41591-018-0251-z.

DOI:10.1038/s41591-018-0251-z

PMID:30361510

Abstract

In the version of this article originally published, there was an error in Fig. 2b. RECIST ORR and pCR were both listed as 25%. RECIST ORR was actually 73%, and pCR was 45%. Also, an author's name was incorrect in the author list. Danny K. Wells should have been listed as Daniel K. Wells. The errors have been corrected in the print, HTML and PDF versions of this article.

摘要

在本文最初发表的版本中，图2b存在一处错误。RECIST标准的客观缓解率（ORR）和病理完全缓解（pCR）均列为25%。实际上，RECIST标准的ORR为73%，pCR为45%。此外，作者列表中的一位作者姓名有误。丹尼·K·韦尔斯（Danny K. Wells）应列为丹尼尔·K·韦尔斯（Daniel K. Wells）。本文的印刷版、HTML版和PDF版中已对这些错误进行了更正。